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INTRODUCTION
Chronic lung disease (CLD) is still one of the major causes
of morbidity and mortality in very low birth weight infants
(VLBWI). From the early 1980s, dexamethasone has been
administered to ventilator-dependent infants with CLD, as
several reports that dexamethasone improves the lung func-
tion and enables earlier extubation were published (1, 2). In
the 1990s, postnatal dexamethasone was administered to
preterm infants almost as a routine to reduce the time spent
on the ventilator and to prevent CLD (3). However, it has
been known that although postnatal dexamethasone reduces
the length of assisted ventilation and the incidence of CLD
both at the 28th day of life and at the 36th postmenstrual
week, it does not reduce the length of hospital stay and mor-
tality ultimately (4-9). Moreover, postnatal dexamethasone
has been reported to be able to produce not only short-term
adverse reactions such as gastrointestinal bleeding, intestinal
perforation, sepsis, meningitis, and hyperglycemia, but also
long-term adverse reactions such as adrenal suppression and
growth failure (10-15). Even more remarkably, recently, there
has been a series of reports that the use of postnatal dexa-
methasone is associated with developmental delay and cere-
bral palsy (16-19). Therefore, nowadays there is a trend not
to use postnatal dexamethasone routinely simply for the pre-
vention of CLD in many neonatal intensive care units (NICU)
(20-22). Similarly, in our NICU, considering the potential
harm of postnatal dexamethasone to the developing brain,
we have been reducing the use of postnatal dexamethasone
gradually. We have attempted to confine postnatal dexa-
methasone therapy to infants who were still ventilator-depen-
dent beyond the second week of life and showed ongoing dete-
rioration in ventilator settings and radiological finding for
more than 3 to 7 consecutive days. Moreover, in case of post-
natal dexamethasone therapy, we have tried to defer it after
the second week of life, and use it in a low dose. However,
there have been persistent concerns about the increased risk
for the CLD due to the decreased use of postnatal dexametha-
sone (23, 24). Nevertheless, there are few studies looking at
the change in the incidence of CLD according to the decreased
use of postnatal dexamethasone. Therefore, we did this study
to delineate the change in the incidence of CLD according
to the gradual reduction of postnatal dexamethasone use in
VLBWI in our NICU.
Chang Won Choi, Jong Hee Hwang,
Jae Won Shim*, Sun Young Ko
� ,
Eun Kyung Lee
� , Sung Shin Kim
� ,
Yun Sil Chang, Won Soon Park,
Son Moon Shin
�
Department of Pediatrics, Samsung Medical Center,
Kangbuk Samsung Hospital*, Samsung Cheil Hospital
� ,
Sungkyunkwan University School of Medicine, Seoul;
Bucheon Hospital
� , Soonchunhyang University College
of Medicine, Bucheon, Korea
Address for correspondence
Yun Sil Chang, M.D.
Department of Pediatrics, Samsung Medical Center,
Sungkyunkwan University School of Medicine,
50 Ilwon-dong, Kangnam-gu, Seoul 135-710, Korea
Tel : +82.2-3410-3528, Fax : +82.2-3410-0043
E-mail : yschang@smc.samsung.co.kr
514
J Korean Med Sci 2004; 19: 514-8
ISSN 1011-8934
Copyright � The Korean Academy
of Medical Sciences
Decreasing Incidence of Chronic Lung Disease Despite the Gradual
Reduction of Postnatal Dexamethasone Use in Very Low Birth Weight
Infants
Dexamethasone has been widely used in very low birth weight infants (VLBWI)
weighing less than 1,500 g at birth for the prevention or treatment of chronic lung
disease (CLD). Recently, however the use of dexamethasone is being reduced, as
its association with abnormal neurodevelopmental outcome is known. On the other
hand, there have been persistent concerns about the increased risk of CLD accord-
ing to the reduction of postnatal dexamethasone use. Hence, we did a retrospective
cohort study to delineate the change in the incidence of CLD according to the reduc-
tion of dexamethasone use in VLBWI. The medical records of 559 VLBWI admit-
ted to neonatal intensive care unit at Samsung Medical Center between Novem-
ber 1994 and December 2002 were reviewed with a focus on the use of postnatal
dexamethasone and the incidence of CLD. The use of postnatal dexamethasone
has significantly decreased over the study period. Especially, the use of high-dose
regimen has markedly decreased. The day when postnatal dexamethasone thera-
py was begun has also been significantly delayed. The incidence of CLD has sig-
nificantly decreased over the same period. In conclusion, the incidence of CLD has
not increased despite the decreased use of postnatal dexamethasone.
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MATERIALS AND METHODS
Five hundred fifty nine VLBWI weighing less than 1,500
g at birth who were admitted to NICU unit at Samsung Medi-
cal Center between November 1994 and December 2002
were enrolled.
To see the trends over time, we divided the study period
arbitrary by a two-year interval into four eras: Era 1, Novem-
ber 1994-December 1996; Era II, January 1997-December
1998; Era III, January 1999-December 2000; Era IV, January
2001-December 2002. We reviewed the medical records of
subject infants with a focus on following variables: Demogra-
phic variables including birth weight, gestational age, and
sex; Clinical characteristics including chorioamnionitis, res-
piratory distress syndrome (RDS), patent ductus arteriosus
(PDA), retinopathy of prematurity (ROP) requiring laser or
cryotherapy, high grade intraventricular hemorrhage (IVH
≥grade III, Volpe’s grading system, 25), periventricular leuko-
malacia (PVL), the extent of initial physiological weight loss,
the length of synchronized intermittent mandatory ventila-
tion (SIMV), the length of nasal continuous positive airway
pressure (NCPAP), the length of supplemental oxygen (frac-
tional concentration of oxygen, FiO2≥0.3), and mortality;
Variables associated with postnatal dexamethasone therapy
and CLD including the use of antenatal steroid, the use of
postnatal dexamethasone, the day when dexamethasone ther-
apy was begun, the dose of dexamethasone used, and the inci-
dence of CLD at the 28th day of life and at the 36th postmen-
strual week.
Gestational age was based on obstetrical record and survival
was defined as when a VLBWI left the hospital alive fulfill-
ing the indication of discharge in our NICU: weighing over
1,800 g and gaining weight steadily about 20-30 g/day; abil-
ity to maintain temperature in an open crib; no need for any
parenteral drugs or fluids. Chorioamnionitis was defined as
histological chorioamnionitis or umbilical cord vasculitis of
grade 2 or greater according to the grading system suggest-
ed by Salafia et al. (26) and assessed by a single pathologist.
The diagnosis of RDS required the presence of respiratory
distress, increased oxygen requirement (FiO2≥0.4) and radi-
ological and laboratory findings consistent with RDS in the
absence of the evidence of other causes of respiratory distress.
PDA was diagnosed by echocardiography and only sympto-
matic cases were identified. A single pediatric ophthalmolo-
gist made the diagnosis and the treatment decision of ROP.
IVH and PVL were assessed with cranial ultrasonography by
a single pediatric radiologist. CLD was defined by the need
for supplemental oxygen (FiO2≥0.3) at the 28th day of life
or at the 36th postmenstrual week with consistent radiolog-
ical finding. In our NICU, postnatal dexamethasone therapy
regimen was either high-dose or low-dose. High-dose regimen
was as follows: starting at 0.5 mg/kg/day divided every 12 hr
for 48 hr, then halving the dose every 48 hr for the next 5
days completing a total of 7 day-regimen. Low-dose regimen
was the same as high-dose regimen except that the starting
dose was 0.2 mg/kg/day. 
All categorical variables were designated as percent (%),
and continuous variables were designated as mean±standard
deviation. We sought to see the trends in the variables across
the four study eras. For this purpose, we used score test for
trend (Jonckheere-Terpstra test for continuous variables, and
linear by linear association for categorical variables). We used
SPSS version 11.5 for these statistical analyses. p-value lower
than 0.05 was regarded significant.
RESULTS
The trends in demographic and clinical characteristics
across the four study eras 
There were no significant difference in gestational age and
sex by the four study eras (Table 1). However, birth weight
showed a significant trend to decrease as the time elapses from
era I to era IV (p<0.01). There were no significant differences
in the incidence of RDS, PDA, ROP requiring laser and
cryotherapy, and IVH (≥grade III) by the four study eras
except the incidence of PVL that revealed a significant trend
Era I 
n=106 
(’94-’96)
Era II
n=140
(’97-’98)
Era III
n=116
(’99-’00)
Era IV
n=197
(’01-’02)
p-
value
�
Birth weight (g)1,172±2191,145±2521,118±248 1,087±262<0.01
Gestational 29
+4±2
+5 29
+2±2
+3 29
+0±2
+4 28
+5±2
+5 NS
age (wk)
Male sex (%) 51 51 53 50 NS
CA (%) 17 20 32 26 NS
RDS (%) 58 49 62 58 NS
PDA (%) 52 44 51 52 NS
ROP (%) 8 8 9 7 NS
IVH (%) 11 8 4 5 NS
PVL (%) 12 2 6 4 <0.05
% Initial weight  9±14 10±17 17±20 13±10 <0.001
loss
SIMV length (d) 22±29 15±28 15±35 9±16 <0.001
NCPAP length (d) 2±56 ±10 6±10 8±12 <0.001
Suppl. O2* 9±13 6±86 ±16 2±4 <0.001
length (d)
Hospital stay (d) 62±44 60±37 71±46 63±37 NS
Mortality (%) 19 17 10 9 <0.01
Table 1. Trends in demographic and clinical characteristics of
very low birth weight infants across the four study eras
CA, Chorioamnionitis; RDS, Respiratory distress syndrome; PDA, Patent
ductus arteriosus; ROP, Retinopathy of prematurity that requiring laser
or cryotherapy; IVH, Intraventricular hemorrhage (≥grade III, Volpe’s
grading system); PVL, Periventricular leukomalacia; SIMV, Synchronized
intermittent mandatory ventilation; d, day; NCPAP, Nasal continuous pos-
itive airway pressure. *, Supplemental oxygen (fractional concentration
of inspired oxygen≥0.3); 
�
, p-value of score test for trend (Jonckheere-
Terpstra test for continuous variables; and linear by linear association
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to decrease as the time passes (p<0.05). There were no signif-
icant differences in the length of hospital stay by the study
eras. However, the length of SIMV and supplemental oxygen,
and mortality showed a significant trend to decrease as the
time elapses (p<0.001, p<0.001, p<0.01, respectively), while
the extent of initial physiological weight loss and the length
of NCPAP revealed a significant trend to increase as the time
passes (p<0.001).
The trends in postnatal dexamethasone use and the inci-
dence of CLD across the four study eras 
The use of antenatal steroid showed a significant trend to
increase as the time elapses from era I to era IV (p<0.001).
However, the use of postnatal dexamethasone in VLBWI has
significantly decreased as the time passes (p<0.001) (Table 2).
Especially, the use of high-dose regimen has markedly decreas-
ed (p<0.01), while the use of low-dose regimen did not reveal
a significant trend across the study eras. The incidence of CLD
at the 28th day of life and that at the 36th postmenstrual
week have all decreased significantly as the time elapses with
the latter more evident (p<0.05, p<0.001, respectively).
DISCUSSION
Around the year of 1999, a number of investigators report-
ed that postnatal dexamethasone therapy for the prevention
or treatment of CLD might produce adverse neurodevelop-
mental outcome (11, 16-19, 27, 28). Recognizing this poten-
tial neurodevelopmental risk of postnatal dexamethasone, we
have tried to reduce the use of postnatal dexamethasone for
the prevention or treatment of CLD in our NICU. The results
of present study indicate that in our NICU, the use of post-
natal dexamethasone, especially high-dose regimen has re-
markably decreased as the time elapses from era I to era IV.
Moreover, a large majority of the studies that reported the
neurodevelopmental risk of postnatal dexamethasone dealt
with the early treatment regimen that dexamethsone is given
to VLBWI within the first two weeks of life, particularly with-
in the first four days of life. Therefore, we have also tried to
delay postnatal dexamethasone therapy after the second week
of life. Actually, our results demonstrated a trend that the time
when dexamethasone therapy was begun has been deferred
from 14±7 postnatal day in era I to 29±14 postnatal day
in era IV.
Our results also show that the incidence of CLD has not
increased, instead it has decreased despite the reduced use of
postnatal dexamethasone during the same period. Many fac-
tors might be responsible for this decrease in the incidence
of CLD. In the present study, we observed the trends in the
factors that have been previously known to be associated with
the development of CLD over time during the study period.
Birth weight, gestational age, and the incidence of patholog-
ically proven chorioamnionitis, RDS, and PDA have not
changed significantly during the study period. However, the
extent of initial physiological weight loss, the length of SIMV
and NCPAP showed a significant change over time during
the study period. The extent of initial physiological weight
loss has increased as the time elapses from era I to era IV. This
change in the extent of initial physiological weight loss might
reflect the alteration in fluid management strategy in our
NICU. We applied fluid restriction therapy (less than 80 mL/
kg/day during the first week of life) since 1999. There have
been several reports that excessive fluid administration in the
early postnatal period is associated with the development of
CLD (29, 30). Therefore, it is possible that the increased extent
of initial physiological weight loss might have contributed
to the decreased incidence of CLD during the study period.
However, the effect of fluid restriction therapy on the preven-
tion of CLD remains to be further evaluated by randomized
case-control study. The decrease in the length of SIMV and
the increase in the length of NCPAP are related to each other,
because we have tried to wean the infants from SIMV to
NCPAP as soon as possible since the latter half of the study
period. Early weaning from SIMV to NCPAP is one of the
strategies to reduce the ventilator-induced lung injury, and
has also been applied in many other NICUs (20-22). Its pre-
ventive effect on CLD is supported by several studies (31-33).
In our study, the decrease in the incidence of CLD might be
partly attributable to this weaning strategy. The incidence
of CLD has significantly decreased not only at the 36th post-
menstrual week but also at the 28th day of life. Considering
that in the latter half of the study period, the era III and IV,
the mean day when dexamethasone therapy was begun was
Era I 
n=106 
(’94-’96)
Era II
n=140
(’97-’98)
Era III
n=116
(’99-’00)
Era IV
n=197
(’01-’02)
p-
value
�
Antenatal steroid  24 59 68 76 <0.001
use (%)
Postnatal DXT  49 30 19 20 <0.001
use (%)
High-dose 0.8±1.5 0.2±0.6 0.4±0.9 0.1±0.4 <0.01
(cycle)*
Low-dose 2.2±2.4 2.1±2.1 2.0±1.8 1.4±0.9 NS
(cycle)*
Start day (d)* 14±71 7 ±11 30±23 29±14 <0.001
CLD at 28th  46 37 34 31 <0.05
PND (%)
CLD at 36th  26 19 11 8 <0.001
PMW (%)
Table 2. Trends in the frequency of postnatal dexamethasone
use and the incidence of chronic lung disease at the 28th post-
natal day or at the 36th postmenstrual week across the four study
eras
DXT, Dexamethasone; CLD, Chronic lung disease; PND, Postnatal day;
PMW, Postmenstrual week. *, In case of postnatal dexamethasone use,
p-value of score test for trend (Jonckheere-Terpstra test for continuous
variables, and linear by linear association for categorical variables).Postnatal Dexamethasone and Chronic Lung Disease in Prematurity 517
around end of the 4th week, the decrease in the incidence of
CLD at the 28th day of life in our cohort is not thought to
be the effect of postnatal dexamethasone.
In contrast to the postnatal dexamethasone, the use of ante-
natal steroid to the mothers of VLBWI has increased across
the four study eras. Antenatal steroid is known to facilitate
the fetal lung maturation resulting in the improvement of
the pulmonary function in the postnatal period (34), and is
being widely used routinely when preterm labor is anticipated
unless the case is contraindicated. However, the neurodevel-
opmental adverse effects that antenatal steroid might produce
have been controversial. Baud et al. reported that the VLBWI
whose mothers had been given antenatal betamethasone devel-
oped PVL on cranial ultrasonography 2 times less frequently
than the VLBWI whose mothers had not, while the VLBWI
whose mothers had been given antenatal dexamethasone
developed PVL 1.5 times more frequently than the VLBWI
whose mothers had not (35). Shankaran et al. reported that
there were no differences in the neurodevelopmental progno-
sis of VLBWI according to the use of antenatal steroid (36).
All the more, they asserted that antenatal steroid decreased
the incidence of high-grade (≥grade III) IVH. Similarly,
LeFlore et al. reported that antenatal steroid did not affect
the incidence of PVL and the scores of Bayley Scales of Infant
Development (37). Our results also revealed that the incidence
of PVL has, at least, not increased across the four study eras,
while the use of antenatal steroid has markedly increased dur-
ing the same period. However, according to the study of Jobe
et al.’s, antenatal steroid can cause symmetrical intrauterine
growth retardation (38, 39). From the above contradicting
results, at present, the neurodevelopmental safety of antena-
tal steroid may not be guaranteed yet, and it requires further
investigations. 
Aside from the probable neurodevelopmental risk of ante-
natal steroid, the inverse relationship between the trends in
the frequency of antenatal steroid use and the incidence of CLD
across the study eras suggests a possibility that the decrease
in the incidence of CLD might be due to the increased use of
antenatal steroid considering its beneficial effect to the lung
function. However, that possibility might be low, because the
incidence of RDS that is thought to be the ultimate outcome
of the beneficial effect of antenatal steroid did not show a sig-
nificant change over time during the same study period. More-
over, in our recent epidemiologic study to assess the risk fac-
tors for CLD in out NICU, RDS was not a significant risk
factor for CLD (40).
Our results demonstrated that although the use of postna-
tal dexamethasone has been reduced, the incidence of CLD
has not increased. The incidence of CLD has rather decreased.
This favorable outcome is thought to be attributable to the
introduction of other measures for the reduction of the lung
injury such as early weaning from SIMV to NCPAP and fluid
restriction therapy in the early postnatal period. Therefore,
as long as the possibility that postnatal dexamethasone pro-
duces neurodevelopmental adverse effect remains, it may be
desirable to refrain from the routine use of postnatal dexam-
ethasone for the prevention of CLD and restrict postnatal dex-
amethsone therapy to the ventilator-dependent VLBWI who
aggravates relentlessly clinically and radiologically beyond
the second week of life.
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